

# Stock Sentiment Analysis Report

Exact Sciences (EXAS)

Analysis Period: 2026-03-02 to 2026-04-01 (30 days)

Generated: 2026-04-01 09:21:21

## Executive Summary

### Executive Summary: Exact Sciences (EXAS) Sentiment Analysis

Exact Sciences (EXAS) exhibited a largely mixed sentiment profile during the period of March 2 to April 1, 2026, with a slight positive bias. Out of 133 analyzed items, 47 were positive, while 43 were negative and 43 were neutral. Key positive drivers stemmed from strong corporate culture recognition and brand visibility. Conversely, negative sentiment was primarily influenced by broader industry challenges related to cancer research, treatment efficacy, and unmet needs in colorectal cancer screening.

The most significant positive driver was Exact Sciences' recognition with the Gallup Exceptional Workplace Award for the third consecutive year, signaling robust employee engagement and a positive work environment. Brand visibility was also enhanced by the Cologuard Classic PGA Tour Champions event. Conversely, significant negative sentiment arose from critical discussions questioning the efficacy of cancer blood tests, directly impacting EXAS's core diagnostic business. Calls for increased funding for colorectal cancer research also contributed to negative sentiment, highlighting persistent challenges in the field. Overall, the period reflects a balance between internal operational strengths and external industry-wide pressures.


## Sentiment Breakdown

Category	Count	Percentage
Positive	47	35.3%
Negative	43	32.3%
Neutral	43	32.3%
<b>Total</b>	<b>133</b>	<b>100.0%</b>

**Overall Sentiment: MIXED**

## Sentiment Trend Over Time

### Exact Sciences (EXAS) - Sentiment Trend (30 Days)



## Key Findings

Finding
✓ Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year
✓ Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year
✓ What to know about Cologuard Classic in Tucson on PGA Tour Champions
✗ Loss of luminal lineage drives resistance to next-generation ER $\alpha$ antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.
✗ Colorectal Cancer Advocates Urge Congress to Fund New Research
✗ Cancer blood tests are everywhere. Do they really work?

## Top Positive Events

Title	Source	Date	Score
Exact Sciences Named Gallup Exceptional Workplace ...	alpha_vantage	2026-03-04	0.834
Exact Sciences Named Gallup Exceptional Workplace ...	alpha_vantage	2026-03-03	0.834
What to know about Cologuard Classic in Tucson on ...	news	2026-03-16	0.778

Intuitive Surgical Upgraded to Buy by Citi — Plus ...	news	2026-03-11	0.727
Trump: If Iran doesn't FULLY OPEN, WITHOUT THREAT,...	reddit	2026-03-22	0.724

## Top Negative Events

Title	Source	Date	Score
Loss of luminal lineage drives resistance to next-...	pubmed	2026 Apr 1	-1.000
Colorectal Cancer Advocates Urge Congress to Fund ...	news	2026-03-27	-0.945
Cancer blood tests are everywhere. Do they really ...	news	2026-03-04	-0.907
Marking National Colorectal Cancer Awareness Month...	alpha_vantage	2026-03-04	-0.869
Villains that were defeated by being given exactly...	reddit	2026-03-04	-0.818